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ABSTRACT
Ovarian cancer is the most lethal gynecological malignancy, primarily because 
its origin and initiation factors are unknown. A secretory murine oviductal epithelial 
(MOE) model was generated to address the hypothesis that the fallopian tube is an 
origin for high-grade serous cancer. MOE cells were stably altered to express mutation 
in p53, silence PTEN, activate AKT, and amplify KRAS alone and in combination, to 
define if this cell type gives rise to tumors and what genetic alterations are required 
to drive malignancy. Cell lines were characterized in vitro and allografted into mice. 
Silencing PTEN formed high-grade carcinoma with wide spread tumor explants 
including metastasis into the ovary. Addition of p53 mutation to PTEN silencing did 
not enhance this phenotype, whereas addition of KRAS mutation reduced survival. 
Interestingly, PTEN silencing and KRAS mutation originating from ovarian surface 
epithelium generated endometrioid carcinoma, suggesting that different cellular 
origins with identical genetic manipulations can give rise to distinct cancer histotypes. 
Defining the roles of specific signaling modifications in tumorigenesis from the 
fallopian tube/oviduct is essential for early detection and development of targeted 
therapeutics. Further, syngeneic MOE allografts provide an ideal model for pre-clinical 
testing in an in vivo environment with an intact immune system.
INTRODUCTION
Ovarian cancer is a heterogeneous disease 
composed of several histotypes including mucinous, clear 
cell, endometrioid, low-grade and high-grade serous. In 
the United States, 23,000 women will be diagnosed and 
14,000 will succumb to these diseases each year [1]. High-
grade serous carcinoma (HGSC) is the most common 
and lethal histotype and is suggested to arise from the 
fallopian tube fimbria. Putative fallopian precursor, lesions 
are thought to arise from the mutation of p53, followed 
by subsequent oncogenic events that confer expansion 
into serous tubal intraepithelial carcinoma (STIC) and 
ultimately into HGSC [2]. HGSC are primarily diagnosed 
at the metastatic stage (75% of cases) and are treated with 
debulking surgery and a combination of paclitaxel and 
carboplatin, but patients often develop chemoresistance 
[3]. Defining the molecular events leading to HGSC 
carcinogenesis and progression from the fallopian tube 
is essential for identification of targets for early detection 
and personalized drug therapy.
Murine models of HGSC originating from the 
fallopian tube equivalent, the oviductal epithelium, reveal 
that these cells can give rise to tumors. These murine 
models utilize the PAX8-TetOn-Cre promoter to drive 
the deletion of PTEN, BRCA1 or 2, and mutation of p53 
in combination, as well as deletion of PTEN together 
with deletion of p53 [4]. These models produced tumors 
that were highly metastatic, colonized the ovaries, and 
expressed oviductal markers. Interestingly, another 
murine model with floxed alleles of PTEN and KRAS 
developed high-grade endometrioid carcinoma when 
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exposed to adenovirus encoding for Cre-recombinase 
regardless of the tissue type targeted (ovarian surface or 
oviductal epithelium [5]). A further model utilizing the 
MISRII promoter driving Cre-recombinase expression 
to delete PTEN alone or in combination with DICER 
in oviductal stromal cells forces a stromal-to-epithelial 
derived high-grade tumor type [6]. Unfortunately, despite 
the advantages of using the Cre-Lox system to generate 
murine models, the limited viral infectivity of the 
oviduct epithelium and the inability to target the oviduct 
specifically with promotor driven Cre-recombinase 
without impacting additional cell types could mask or 
confuse the question of cellular origin [7]. Furthermore, 
although p53 is mutated in 96-100% of HGSC tumors 
and is thought to be one of the earliest molecular changes 
in fallopian derived HGSC, animals with mutation in 
p53 alone have not yet been characterized. Additionally, 
mutation in p53 has not been examined with the loss of 
PTEN, in the absence of BRCA mutation, which is of 
interest as ~70-80% of HGSC tumors are spontaneous and 
not the result of mutation or methylation in BRCA (11). 
Moreover, human fallopian cell models have demonstrated 
the importance of KRAS and c-myc in generating HGSC 
and mucinous histotypes from fallopian tube epithelium 
[8-10]. In these human models, p53 is either silenced or 
inactivated by SV40T, which hinders the ability to study 
the impact of gain-of-function p53 mutations, which 
represent the vast majority of mutations in HGSC.
The Cancer Genome Atlas Network demonstrated 
that several key pathways are altered in HGSC, yet many 
of them are not altered strictly through mutation [11]. For 
example, PTEN is rarely mutated in HGSC but instead 
tumors demonstrate a loss of heterozygosity. Similarly, 
tissue microarray studies demonstrate AKT activation 
through phosphorylation occurs early in tumorigenesis and 
is independent of PTEN, AKT, and PIK3Ca mutation [12, 
13]. KRAS is also rarely mutated, but instead is amplified 
in many tumors. As many HGSC tumors are studied in 
a late stage, metastatic setting, it is unclear whether 
altered pathways are initiators of disease or if they are 
compounded genetic alterations.
The purpose of this study was to engineer 
clonogenic murine oviductal epithelial (MOE) models 
with individual and multiple pathway modifications to 
mimic changes detected in human HGSC tumors. The 
ability to study mutant p53 alone and in combination with 
several other events allows for clarification of its role and 
its ability to modify other pathways. Similarly, models 
were constructed with PTEN silenced, but not completely 
deleted, similar to loss of heterozygosity in HGSC and 
with AKT constitutively activated by myristolation. 
Lastly, the G12V mutation was utilized to activate KRAS 
function. These unique MOE cell models indicate that 
loss of PTEN alone is sufficient to drive tumorigenesis 
and widely spread metastasis in the peritoneal cavity. 
Mutation of p53 did not enhance this process, while 
mutation of KRAS significantly decreased survival time. 
These models indicate that specific mutation in oviductal 
epithelium can produce tumors with unique morphologies 
and specific secondary sites of tumor spread, including the 
ovary suggesting a role for this tissue in the dissemination 
of disease. Finally this study validates that novel MOE 
models can be utilized in syngeneic allografts allowing 
for preclinical therapeutic development in an immune-
competent in vivo environment.
RESULTS
MOE cells stably expressing targets altered in 
HGSC patients
To examine the effects of genetic alterations similar 
to those observed in HGSC patients, MOE cells were 
stably transfected with mutation in p53 R273H (p53R273H), 
silenced PTEN via shRNA (PTENshRNA), activation of 
AKT via myristolation (AKTMYR) and activating mutation 
in KRAS G12V (KRASG12V) (Suppl. Table 1). In addition 
cell lines harboring multiple genetic modifications were 
created, as often multiple mutations are required for 
oncogenic transformation. These cells were validated to 
express targets of interest via western blotting (Suppl. Fig 
1A) compared to parental wildtype and scrambled shRNA 
control MOE cell lines. Signaling downstream of genetic 
manipulations was also altered as expected, demonstrating 
that both the targets themselves and their signaling 
pathways were functionally impacted (Suppl. Fig 1B). 
Silencing PTEN increases MOE cell proliferation 
and addition of p53R273H, AKTMYR, or KRASG12V 
promotes in vitro transformation
Stably modified MOE cells were characterized 
for phenotypic changes in vitro, specifically enhanced 
proliferation or anchorage independent growth. SRB assay 
determined PTENshRNA MOE had enhanced cell growth 
at 5 days (9.2±0.4 fold, p = 0.01) when compared with 
wildtype parental MOE cells (6.2±0.3 fold) or scrambled 
shRNA control MOE cells (7.1±0.5 fold, Figure 1A). 
MOE cells harboring PTENshRNA in combination with 
either p53R273H or KRASG12V also displayed enhanced 
proliferation (10.6±1.1 fold, p = 0.02 and 10.8±0.7 fold, p 
= 0.01 respectively). The expression of p53R273H,KRASG12V, 
or AKTMYR alone in MOE cells did not alter proliferation 
(Figure 1B) [14]. Addition of AKTMYR to generate 
PTENshRNA/AKTMYR MOE abrogated the enhanced growth 
seen with PTENshRNA alone. Further, MOE cells harboring 
triple manipulation; PTENshRNA/AKTMYR/KRASG12V 
exhibited reduced cell growth (4.9±0.7 fold increase, p = 
0.02). 
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In vitro transformative potential was investigated 
using a soft agar assay for anchorage independent growth. 
Wildtype and scrambled shRNA control MOE cells did 
not form colonies in soft agar (Figure 1C). Similarly, 
MOE cells with single genetic alterations were unable 
to form colonies [14]. However, MOE cells with PTEN 
knockdown in combination with another alteration did 
form colonies in soft agar (Figure 1D); PTENshRNA/p53R273H 
(5-fold increase compared to scrambled shRNA control), 
PTENshRNA/AKTMYR (3-fold increase), and PTENshRNA/
KRASG12V (22-fold increase). MOE cells stably transfected 
with three genetic alterations; PTENshRNA/AKTMYR/ 
KRASG12V, were also transformed in vitro, with a 7-fold 
increase in colony formation. 
Transformed PTENshRNA MOE cell grafts mimic HGSC 
tumors in patients
To test tumorigenic potential of MOE cells 
in vivo, genetically engineered MOE cell lines and 
parental wildtype and scrambled shRNA controls were 
allografted into athymic mice subcutaneously (s.c) and 
intraperitoneally (i.p.) and tumorigenesis was assessed 
over a 6 month period (Figure 2A). Mice grafted with 
wildtype or scrambled shRNA control MOE had no 
evidence of tumor burden. MOE with single genetic 
changes to either p53R273H or KRASG12V also did not form 
disease in athymic mice [14]. However, several MOE 
models generated tumors. Subcutaneous tumor growth 
was tracked via weekly caliper measurement (Figure 2B). 
When tumor burden reached a moribund stage animals 
were sacrificed, s.c. tumors weighed and i.p. disease 
assessed (Table 1). 
Figure 1: Genetically engineered MOE have tumorigenic characteristics in vitro. A. MOE cells stably altered with PTENshRNA, 
PTENshRNA/p53R273H, and PTENshRNA/KRASG12V were significantly more proliferative than scrambled shRNA transfected and parental MOE 
cells (data not shown) after 5 days in culture (n = 8). B. Proliferation was not altered in cells harboring AKTMYR or PTENshRNA/AKTMYR. 
PTENshRNA/ AKTMYR/KRASG12V MOE cells had a reduction in proliferation compared to scrambled shRNA control (n = 5). C and D. 
Anchorage independent growth occurred in several engineered MOE cells as demonstrated by colony formation in vitro, specifically 
cells with PTENshRNA in combination with other genetic alterations (denoted with arrows). Parental MOE cell (WT), SCR, and MOE cells 
harboring single genetic alterations did not form colonies. *p ≤ 0.05, **p ≤ 0.01 and ***p ≤ 0.001 as determined by t-test.
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Table 1: Summary of MOE allografted animal survival and tumor formation.
MOE Cell Type Survival (days) S.C. Tumor Weight (mg) Peritoneal Disease
Wildtype (WT) no mortality N/A N/A
Scrambled shRNA (SCR) no mortality N/A N/A
PTENshRNA 147 ± 21 376.8 ± 107.1 100% (4/4)
PTENshRNA / p53R273H 130 ± 8 771.1 ± 198.1 60% (3/5)
PTENshRNA / AKTMYR no mortality 69.93 ± 14.1 40% (2/5)
PTENshRNA / KRASG12V 45  ±  1 520.1 ± 38.9 100% (6/6)
PTENshRNA / AKTMYR / KRASG12V 164  ±  8 347.5 ± 88.7 67% (4/6)
Table 2: Immunohistochemical analysis on MOE-derived tumors.
PTENshRNA PTEN
shRNA / 
p53R273H
PTENshRNA / 
KRASG12V
PTENshRNA / 
AKTMYR
PTENshRNA /
AKTMYR/
KRASG12V
CK8 + + + - +
PAX8 + + + + +
WT1 + +/- + - +/-
Ki67 50-60% 40-50% 60-70% 20-30% 30-40%
p53 1+ / 2+ 1+ 1+ - -
Table 3: Sites of MOE peritoneal explant colonization.
PTENshRNA PTEN
shRNA/ 
p53R273H
PTENshRNA/ 
KRASG12V
PTENshRNA/ 
AKTMYR
PTENshRNA/
AKTMYR/
KRASG12V
PTENshRNA/
KRASG12V
SYNGENEIC
Reproductive 
Tract 4 / 4 3 / 5 6 / 6 0 / 5 3 / 6 0 / 5
G.I. Tract / 
Omentum 4 / 4 3 / 5 6 / 6 1 / 5 1 / 6 3 / 5
Diaphragm 3 / 4 1 / 5 4 / 6 0 / 5 0 / 6 2 / 5
Pancreas 4 / 4 2 / 5 4 / 6 2 / 5 4 / 6 4 / 5
Kidney 0 / 4 0 / 5 1 / 6 0 / 5 0 / 6 0 / 5
Liver/Lung 1 / 4 0 / 5 1 / 6 0 / 5 0 / 6 1 / 5
Ascites 1 / 4 0 / 5 1 / 6 0 / 5 0 / 6 5 / 5
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PTENshRNA MOE cells formed large s.c. tumors 
(376.8±107.1 mg, Figure 3A) and were sacrificed at 
147±21 days post grafting. Further, PTENshRNA MOE 
formed tumor explants throughout the peritoneal cavity 
(4/4 animals, 100%, Figure 3B), including spread to 
the reproductive tract (4/4 animals), G.I./omentum (4/4 
animals), and the diaphragm (3/4 animals, Table 2) 
Further, kidney, liver and lung were relatively disease free, 
a disease pattern that is common in patients, demonstrating 
that malignancy of oviductal epithelial origin mimics 
HGSC peritoneal colonization. In addition to the 
analogous disease spread, one of the four PTENshRNA MOE 
host animals (25%) also developed ascites fluid, another 
hallmark of HGSC tumorigenesis in women. When host 
reproductive tracts were excised, metastasis into the bursa 
and spread to the ovaries was noted (Figure 3C).
Figure 2: MOE cells form subcutaneous (s.c) and intraperitoneal tumors in an allograft model. A. Several pathway 
modified MOE models were capable of tumorigenesis when grafted into athymic mice and had markedly reduced survival after 6 months in 
vivo (n = 4-6 mice per group). B. S.C. tumor growth was tracked via weekly caliper measurements. No growth was seen in parental (WT) 
or scrambled shRNA (SCR) control cell lines whereas pathway modified MOE cells formed large s.c. tumors. Arrows denote where animals 
were humanely sacrificed due to tumor burden, which modified the average tumor size. 
Figure 3: PTENshRNA MOE form high-grade carcinoma in vivo. A. PTENshRNA MOE grafted mice formed large s.c. tumors 
(dashed outline) and B. disseminated i.p. disease (dashed outline). C. Notably, MOE tumors spread to the ovaries of grafted animals 
(arrows). Immunohistochemical analysis of PTENshRNA MOE via D. H&E, E. CK8, F. PAX8, G. WT1, H. p53, and I. Ki67 staining 
determined the tumors to be moderately differentiated high-grade carcinomas of oviductal epithelial origin. Scale bars equal 50 microns.
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Immunohistochemical analysis of PTENshRNA MOE 
derived tumors and subsequent pathological analysis 
confirmed the tumors were moderately differentiated 
high-grade carcinoma of oviductal epithelial origin. This 
was determined by moderate nuclear atypia seen in H&E 
staining (Figure 3D). Tumors consisted of epithelioid 
cells, primarily solid and nesting growth patterns with 
areas of poorly formed glandular structure. Cytokeratin 
8 (CK8) and PAX8 staining (Figure 3E-3F) confirmed 
the tumors to be of oviductal epithelial origin. PTENshRNA 
MOE derived tumors also expressed the serous marker 
WT1 (Figure 3G), were highly proliferative (50-60% Ki-
67 positive, Figure 3H) and demonstrated stabilized p53 
protein expression via strong and diffuse immunoreactivity 
(Figure 3I).
Mutation in p53 does not enhance PTENshRNA MOE 
phenotype
Animals grafted with PTENshRNA/p53R273H MOE cells 
had similar s.c. disease formation (Figure 4A) and survival 
rates to that of PTENshRNA MOE grafted animals (130±8 
days post grafting). However, peritoneal tumor burden 
was reduced, as not all PTENshRNA/p53R273H allograft mice 
presented with peritoneal disease (3 of 5 animals (60%), 
Figure 4B). Of the mice that developed i.p. disease, fewer 
malignant explants were found. Despite fewer sites of 
dissemination, animals with peritoneal disease had tumors 
in their ovaries (Figure 4C-4D), with infiltration noted via 
CK8 and PAX8 positive tumor cells engulfing the ovaries 
and leaving follicular structures surrounded by MOE-
derived tumors.
PTENshRNA/p53R273H MOE derived tumors were 
pathologically assessed and determined to be poorly 
differentiated, high-grade tumors with features of 
sarcomatoid carcinoma. Tumor cells had high nuclear 
atypia with little to no glandular structure (Figure 4E). 
Cells were of MOE origin, characterized by their diffuse 
immunoreactivity for CK8 and PAX8 (Figure 4F-4G), 
serous marker WT1 expression was variable (Figure 4H). 
PTENshRNA/p53R273H tumors were highly proliferative (40-
50% of cells staining positively for Ki67, Figure 4I) and 
expressed stabilized p53 (Figure 4J).
Figure 4: PTENshRNA/p53R273H MOE form high-grade carcinomas with reduced i.p. spread compared to 
PTENshRNA MOE. A. As with PTENshRNA-alone MOE, PTENshRNA/p53R273H MOE grafted mice formed large s.c. tumors (dashed 
outline) but B. had reduced i.p. disease (dashed outline). C. Despite the reduction in i.p. tumor explants, PTENshRNA/p53R273H MOE, staining 
for CK8 and D. PAX8 preferentially formed disease on the ovaries, with tumor invasion engulfing oocytes (*). Immunohistochemical 
analysis of PTENshRNA/p53R273H MOE via E. H&E, F. CK8, G. PAX8, H. WT1, I. Ki67, and J. p53 staining determined the tumors to be 
poorly differentiated high-grade sarcomatoid carcinoma. Scale bars equal 200 microns (C-D) and 50 microns (E-J).
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Activation of KRAS enhances PTENshRNA 
phenotype
The addition of a mutation in KRAS (G12V) 
to PTENshRNA (PTENshRNA/ KRASG12V) enhanced MOE 
cell carcinogenesis, with an average survival of 45±1 
days. Large s.c. tumors developed quickly (520.1±38.9 
mg, Figure 5A). Ascites fluid (1/6 animals (17%)), vast 
peritoneal disease spread (6/6 animals, 100%, Figure 5B), 
and reproductive explants (6/6 animals, 100%, Figure 5C) 
were found in PTENshRNA/KRASG12V grafted hosts. Tumor 
explants were noted in the ovaries in the majority of 
animals with i.p. disease, while oviducts remained disease 
free in MOE grafted mice (Suppl. Fig. 2).
Immunohistochemical analysis of PTENshRNA/
KRASG12V MOE derived tumors determined them to be 
high-grade carcinomas of oviductal epithelial origin. 
Tumors had solid and sheath growth patterns with high-
grade and pleomorphic nuclear atypia, and brisk of mitosis 
(Figure 5F). As with previous MOE grafts, PTENshRNA/
KRASG12V MOE derived tumors had strong and diffuse 
immunoreactivity for CK8, PAX8, and WT1, consistent 
with oviductal secretory cell origin (Figure 5G-5I). 
PTENshRNA/KRASG12V tumors were highly proliferative (60-
70% Ki67 staining, Figure 5J), which likely contributed to 
enhanced aggression of the disease. p53 was enhanced but 
varied from case to case (Figure 5K).
Myristolation of AKT diminishes MOE tumor 
phenotype
Interestingly, the addition of AKTMYR to PTENshRNA 
(PTENshRNA/AKTMYR) or in combination with PTENshRNA 
and KRASG12V (PTENshRNA/AKTMYR/KRASG12V) resulted in 
reduced tumor burden. PTENshRNA/AKTMYR grafts were not 
lethal after six months, although s.c. tumors 5-fold smaller 
than those found in PTENshRNA MOE mice, were recovered 
at the time of sacrifice (69.93±14.1 mg). Two of five 
animals (40%) had singular metastatic explants, a drastic 
reduction in tumor spread compared to PTENshRNA grafted 
mice. Pathological assessment determined PTENshRNA/
AKTMYR tumors were poorly differentiated high-grade 
sarcomatoid carcinoma. H&E staining revealed extensive 
tumor necrosis and apoptosis (Figure 6A). Tumors were 
hypercellular with high nuclear to cytoplasmic ratio, and 
features of ‘small-cell like’ morphology. Further, tumor 
cells had reduced CK8 and low PAX8 expression (Figure 
6B-6C). The serous marker WT1 was also lost (Figure 
6D). PTENshRNA/AKTMYR s.c. tumors displayed low 
Figure 5: PTENshRNA/KRASG12V MOE give rise to highly-aggressive carcinomas with advanced i.p. spread. A. 
PTENshRNA/KRASG12V MOE grafted mice quickly developed large s.c. tumors (dashed outline) and some hosts developed ascites fluid. B. 
i.p. explants were dispersed throughout the peritoneal cavity including the G.I. tract and diaphragm (dashed outline). C. As with PTENshRNA 
and PTENshrNA/p53R273H grafted animals ovarian tumors were noted staining positively for D. CK8 and E. PAX8. Immunohistochemical 
analysis of PTENshRNA/KRASG12V MOE via F. H&E, G. CK8, H. PAX8, I. WT1, J. p53, and K. Ki67 staining determined the tumors to be 
undifferentiated high-grade carcinomas of oviductal epithelial origin. Scale bars equal 200 microns (D-E) and 50 microns (F-K).
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mitotic indices (20-30% Ki67 staining, Figure 6E), and no 
stabilized p53 expression (Figure 6F).
PTENshRNA/AKTMYR/KRASG12V grafts also produced 
a diminished tumor phenotype when compared to either 
PTENshRNA or PTENshRNA/ KRASG12V grafted animals, 
identified as poorly differentiated high-grade sarcomatoid 
carcinoma, with an over three-fold increase in survival 
compared with PTENshRNA/ KRASG12V grafted mice 
(164±8 days). Only four of six (67%) PTENshRNA/AKTMYR/
KRASG12V grafted mice were moribund prior to the 6 
month experimental timepoint. Resulting s.c. tumors were 
comparable to other lethal MOE allografts (347.5±88.7 
mg). Four of six (67%) PTENshRNA/AKTMYR/KRASG12V 
grafted mice formed peritoneal explants; however disease 
was reduced compared to PTENshRNA or PTENshRNA/ 
KRASG12V, with no animal harboring more than two 
peritoneal explants. Both the reproductive tract and the 
pancreas remained preferential sites of tumor colonization 
(Table 3). 
As with PTENshRNA/AKTMYR, tumors were high-
grade carcinoma with notable nuclear atypia (Figure 
6G). PTENshRNA/AKTMYR/KRASG12V tumors were 
immunoreactive for CK8 and PAX8 although expression 
was diminished compared to lethal MOE models (Figure 
6H-6I). WT1 expression and proliferation were reduced 
(30-40% proliferation, Figure 6J-6K). Moreover, p53 
expression was not stabilized (Figure 6L). These data 
demonstrate that although enhanced phosphorylation of 
AKT is seen in HGSC tumors, enhanced AKT signaling 
does not phenocopy loss of PTEN, with notable alterations 
in tumor spread, p53 stabilization, and expression of 
serous markers such as WT1. 
Therapeutic targeting and syngeneic allografts of 
PTENshRNA/KRASG12V MOE cells
PTENshRNA/KRASG12V MOE cells could be utilized 
to test novel targeted therapeutics prior to human clinical 
trials. To highlight potential pathways for therapeutic 
intervention, PTENshRNA/KRASG12V MOE cells were 
treated with specific chemical inhibitors downstream 
of genetic alterations and subjected to soft agar assay. 
MK2206 (10µM), an allosteric AKT inhibitor, was utilized 
to diminish the effects of PTEN silencing, and U0126 
Figure 6: MOE with AKTMYR had reduced tumor phenotypes. The addition of AKTMYR to PTENshRNA in PTENshRNA/AKTMYR 
MOE grafted mice generated a less aggressive phenotype. Immunohistochemical analysis of PTENshRNA/AKTMYR MOE via A. H&E, B. 
CK8, C. PAX8, D. WT1, E. p53, and F. Ki67 staining determined the tumors to be full of necrotic and regressing cells as well as proliferating 
cells and reduction of epithelial markers, resulting in poorly differentiated high-grade mesenchymal-like carcinomas. Similarly, PTENshRNA/
AKTMYR/KRASG12V MOE had a reduced phenotype compared to either PTENshRNA or PTENshRNA/KRASG12V MOE cells. Pathological 
evaluation of tumors stained for via G. H&E, H. CK8, I. PAX8, J. WT1, K. p53, and L. Ki67 revealed the PTENshRNA/AKTMYR/KRASG12V 
derived tumors were poorly differentiated high-grade epithelioid sarcomas. Scale bars equal 50 microns.
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(10µM), a MEK1/2 inhibitor, was utilized to inhibit 
uncontrolled signaling downstream of KRAS mutation 
(Figure 7A). U0126 reduced colony formation by 60%, 
MK2206 by 78% and combined inhibitor treatment by 
84%, demonstrating both pathways are required for colony 
formation , inhibition of which is able to suppress in vitro 
transformation. 
Additionally, PTENshRNA/KRASG12V cells were 
utilized to demonstrate the potential for MOE cells as a 
syngeneic model, allowing for preclinical investigation of 
novel therapeutics in the presence of an immune system. 
FVB mice were i.p. allografted with PTENshRNA/KRASG12V 
MOE and developed high-grade carcinomas. Interestingly, 
immno-competent FVB host animals had reduced survival 
(28±0.2 vs 45±1 days, Figure 7B). This was likely due 
to increased occurrence of ascites fluid build-up, seen 
in all syngeneic grafted animals. Tumor explants were 
of a similar morphology and disease pattern to that seen 
previously in athymic allografted animals (Figure 7C-7F, 
Table 3). MOE models could be utilized for therapeutic 
development in the presence of an immune-competent in 
vivo environment.
DISCUSSION
To address origin and initiation factors leading to 
HGSC tumorigenesis, murine oviductal epithelial cells 
(MOE) were modified to stably express alterations in 
key pathways affected in HGCS patients. This study 
demonstrated that oviductal epithelium can give rise 
to tumors similar to those identified in HGSC patients 
from characterized genetic drivers of disease. In vitro 
characterization of MOE cells demonstrated specific 
genetic alterations, namely PTENshRNA alone and in 
combination with KRASG12V, p53R273H, and AKTMYR 
induced phenotypic changes in proliferation and anchorage 
independent growth. In vivo characterization in allografted 
athymic and subsequent syngeneic murine model produced 
MOE derived high-grade carcinomas, which resembled 
HGSC found in women both in pathological staining and 
pattern of disease spread. These data support the fallopian 
tube/oviduct as a potential origin for HGSC, expand upon 
previous studies of key genetic regulators in human and 
murine models, and provide a novel immune-competent 
model for biomarker and therapeutic development.
Silencing PTEN alone initiated tumor formation 
from MOE cells. Studies using PAX8 to drive Cre-
recombinase mediated deletion of PTEN did so only 
in combination with other genes such as BRCA1/2 or 
mutant p53 R270H [4]. Importantly, recent evidence 
indicates that PTEN loss is more common than initially 
thought in HGSC when epithelium are isolated away from 
stromal contaminants [15]. This is the first publication 
to demonstrate that PTEN silencing alone in a murine 
model of oviductal epithelium can generate tumors. PTEN 
loss also drives tumor formation from the endometrium, 
thyroid, and prostate epithelium indicating that multiple 
Figure 7: MOE cells as preclinical models for therapeutic development. A. Treatment with the AKT inhibitor (MK2006 (10 
µM), counteracts PTEN suppression) or with the MEK inhibitor (U0126 (10 µM), inhibits signaling downstream of KRAS) represses 
colony formation in soft agar compared to vehicle-treated (DMSO) control (n = 6). B. Syngeneic PTENshRNA/KRASG12V allografts have 
drastically reduced survival time compared to athymic PTENshRNA/KRASG!2V allografts. C. Tumors from syngeneic PTENshRNA/KRASG!2V 
allografted mice were similar in morphology to those of athymic hosts as determined via H&E staining and expression of D. CK8, E. PAX8, 
and F. Ki67 staining. Scale bars equal 50 microns.
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types of hormone responsive epithelium are dependent 
on expression of PTEN to block tumor formation [16]. 
Another Cre-recombinase murine model driven by MISRII 
to delete PTEN alone did not demonstrate a phenotype, 
but this was likely due to Cre-mediated excision in the 
oviductal stroma and ovarian surface epithelium rather 
than the oviductal epithelium and suggests that PTEN 
governs different pathways in these cell types [6, 17]. 
In agreement with this hypothesis, findings from our 
lab indicated that PTEN silencing in murine OSE was 
unable to generate soft agar colonies [18]. Moreover, a 
publication recently attempted to intraoviductally inject 
adenovirus into MUC1/KRAS/PTEN floxed mice, which 
resulted in high-grade endometrioid carcinoma; however, 
intraoviductal injections can be leaky, often infecting the 
ovarian surface, and as previous reports suggest, oviductal 
infectivity is limited in vivo and in 3D in vitro cultures [5, 
7]. 
The incorporation of mutant p53 into PTENshRNA 
cells did not enhance proliferation or tumor forming 
potential observed with PTENshRNA alone. These data 
are consistent with studies performed in human samples 
that indicate that mutation in p53 does not correlate 
with changes in tumor progression or survival [19]. In 
fact, mutation of p53 reduced the extent of tumor spread 
in mice with PTENshRNA suggesting that p53 mutation 
functions in a very context specific manner. These results 
are similar to the PAX8-Cre models where the addition 
of mutant p53 to PTEN and BRCA did not dramatically 
impact survival [4]. Previous reports suggest that mutation 
of p53 can slow migration as compared to wildtype [20] 
and that wildtype p53 in OSE derived tumors enhances 
survival [21]. However, mutation in p53 enhances tumor 
formation in the APC/PTEN model of OSE derived 
endometrioid cancer providing evidence that both the 
mutation landscape and the cell of origin impact the 
functional context of p53 mutation and resulting tumor 
histotype [22]. The current study focused on one DNA 
mutation of p53, R273H, the most common mutation 
in HGSC. However, many other mutations are seen in 
HGSC, making it difficult to decipher a general role for 
p53 and how it impacts tumorigenesis from the oviduct.
Data from this study highlight the importance of 
context in the generation of disease; namely the cell of 
origin, the genetic landscape/specific mutations, and the 
site of tumor development, especially when allografted. 
This is highlighted by PTEN silencing alone in the OSE, 
which does not drive tumor formation [23], whereas 
in the oviductal epithelium PTEN loss is sufficient 
for tumorigenesis. We speculate, this variation in 
susceptibility may be due in part to disparity between the 
two cell types; oviductal epithelium, which may be more 
representative of a true epithelium and is highly similar to 
that of other PTEN susceptible epithelial populations, such 
as endometrial epithelium [15], as compared to the OSE, 
which is developmentally less differentiated and more 
characteristic of a mixed mesothelium [24]. The molecular 
signaling landscape also impacts tumor formation, as 
evidenced by PTENshRNA alone and in combination with 
KRAS mutation developing more aggressive peritoneal 
disease as compared to PTENshRNA in combination 
with p53 mutation or activation of AKT. Furthermore, 
tumor histology was influenced by the site of grafting 
as PTENshRNA tumors appeared more epithelioid when 
allografted into the peritoneal cavity, a more orthotopic 
model of HGSC as compared to the subcutaneous space. 
The cell of origin from which a tumor is derived further 
impacts the spectrum of spread. The ovary was a common 
site of infiltration of MOE models that formed peritoneal 
explants. In contrast, despite cell models being derived 
from the oviduct, colonization in the oviduct was not seen. 
In addition to the ovary, the gynecologic tract in general 
was a site of tumor adhesion and growth suggesting that 
the ovaries and uterus express receptors or growth factors 
that help to stimulate colonization. As the rodent ovary 
is surrounded by a bursa, identification of MOE derived 
ovarian tumors indicates metastasis through the bursa 
or through the lymphatic or hematopoietic systems to 
penetrate the ovarian cortex after peritoneal injection. 
Taken together these data highlight the context of disease, 
in particular the cells impacted, the specific pathways 
altered, and the site of tumor growth will influence the 
phenotype and therefore the future use of models for 
preclinical testing.
Overall these findings indicate that the secretory 
epithelium of the oviduct can form tumors that resemble 
the human disease through genetic manipulation of 
pathways that are frequently modified in HGSC. PTEN 
silencing alone was sufficient to drive widespread disease 
and was further enhanced with activation of KRAS but 
not mutation of p53. KRAS mutation enhanced PTENshRNA 
phenotype, while AKTMYR blunted the peritoneal spread 
seen in PTENshRNA and PTENshRNA/KRASG12V MOE cells. 
These data are intriguing as they suggest PTENshRNA 
does not phenocopy AKTMYR and may have functionality 
independent of PI3K/AKT signaling. This is supported by 
previous studies which demonstrated PTEN loss results 
in reduction of p53 expression in tissues and cells [25]. 
Further, it is postulated p53 transcriptional activity is 
modulated by direct PTEN interaction with p300 and 
p53 in the nucleus, a mechanism independent of the AKT 
pathway [26]. However, the difference between PTENshRNA 
and AKTMYR in the present study may also be the result of 
artificial activation of AKT via myristolation, which via 
lipid modification, forces AKT to be presented at the cell 
membrane and thus constitutively activated. As a result, it 
is possible actions of AKT away from the cell membrane, 
such as in the nucleus where it is postulated to interact with 
FOXO family transcription factors may be suppressed in 
this model, thereby creating the differences seen between 
PTEN suppression and AKT activation [27]. Further, 
the construct utilized by this study activates AKT1, and 
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although it is thought that AKT2 and 3 isoforms can 
compensate, evidence suggests they play distinct roles in 
cancer progression [28, 29]. Thus it may be beneficial to 
utilize a cell line incorporating all AKT isoforms, such as 
PI3K activation, to further clarify possible phosphatase-
independent mechanisms by which PTEN promotes 
tumorigenesis. Despite these differences, colony formation 
was disrupted with an AKT small molecule inhibitor in 
cells with absent PTEN. This was also demonstrated with 
the MEK inhibitor U0126 downstream of KRAS function. 
Recent reports demonstrate FOXO3 is differentially 
expressed in p53 signatures and STICs and correlated with 
changes in KRAS and PTEN signaling that may underlie 
alterations from a benign to a malignant phenotype [30]. 
The novel MOE cell model created in this study 
has demonstrated that context of carcinogenesis is 
extremely impactful on the resulting disease, in particular 
the cell of origin and genetic alterations leading to 
tumorigenesis. These models can be used to investigate 
secreted factors that might serve as biomarkers, to 
directly compare against similar OSE models [31] and 
can be allografted sygeneically, thereby allowing for 
the study of tumorigenesis in the presence of immune 
function and immune-modulating therapies. Clarifying 
the mechanisms contributing to HGSC formation will 
inform the development of targeted screening, prevention 
and therapy, thereby impacting HGSC patient prognosis 
and survival.
MATERIALS AND METHODS
Cell culture
MOE were isolated from the oviducts of cycling 
FVB/N mice in accordance with the guidelines of the 
Canadian Council on Animal Care and with institutional 
approval by the University of Ottawa. Cells were 
clonogenically grown from single cells and confirmed 
as oviductal epithelium by expression of PAX2, PAX8, 
and OVGP1 proteins. MOE were cultured as previously 
described [18].
Stable cell development
Parental MOE cells were transfected via TransIT 
LT1 (Mirus Bio, Madison, WI) according to the 
manufacturer’s instructions with plasmids containing 
targets of interest (Suppl. Table 1). Cells were 
clonogenically isolated via antibiotic selection (Suppl. 
Table 1) and validated via qRT-PCR and western blotting.
Western blotting
Cell lysates (30μg) were run on 12% SDS-PAGE 
gels and transferred to nitrocellulose membranes (Fisher 
Scientific, Pittsburgh, PA). Membranes were incubated 
with antibodies targeting proteins of interest overnight at 
4° C (Suppl. Table 2) prior to detection via horseradish 
peroxidase-conjugated secondary antibody (1:1000, Cell 
Signaling, Cambridge, MA) and SuperSignal West Femto 
substrate (Thermo Scientific, Rockford, IL, USA).
Proliferation assay
Sulforhodamine B (SRB) assay was utilized to 
determine cell density as previously described [32]. 
Briefly, MOE were plated at 1,000 cells per well in a 96-
well plate and fixed at varying time points as described. 
Plates were probed with SRB and cell density determined 
by comparison to a cell-matched control plate fixed 2 
hours post plating.
Soft agar colony formation assay
Anchorage independent growth was assessed via 
soft agar assay as previously described [18]. MOE cells 
were seeded at a density of 1.5x105 cells per well in 0.35% 
agarose (Sigma Aldrich, St. Louis, MO) / DMEM (Life 
Technologies, Carlsbad, CA) in a 24-well plate. Cells 
were incubated for 2 weeks, with media changed every 
4 days (DMEM, 1x penicillin/streptomycin (Gibco, 
Carlsbad, CA), 4% FBS (Life Technologies)). Data was 
blinded prior to quantification via ImageJ software (NIH, 
Bethesda, MD). Subsequent assays utilizing inhibitors 
(MK2206 (10μM) and U0126 (10μM)) with DMSO as 
vehicle control, treatments were refreshed every 4 days 
with overlying media.
Study approval
All animals were treated in accordance with the 
NIH guidelines for Laboratory Animals and established 
Institutional Animal Use and Care protocol at the 
University of Illinois at Chicago. 
Allografting
Athymic mice were acquired from (Taconic, 
Germantown, NY) and allografted with MOE cells 
including the parental/wildtype (WT) and scrambled 
shRNA (SCR) control lines 2x106 cells in 300μL 
PBS:matrigel (1:1 vol/vol) subcutaneously (s.c) and 
intraperitoneally (i.p.) 1x107 cells in 300μL PBS. Animal 
weight and s.c. tumor growth (via caliper measurement) 
Oncotarget20511www.impactjournals.com/oncotarget
were tracked weekly and animals sacrificed when tumor 
burden or general health was determined to be moribund. 
Syngeneic grafts were performed in FVB/N mice via i.p. 
injection of 1x107 cells in 300μL PBS. Subcutaneous 
grafts were not performed in immune competent hosts.
Tissue collection and analysis
 At the time of sacrifice, s.c. tumors were 
dissected and weighed, evidence of i.p. disease 
noted and collected along with reproductive and 
gastrointestinal tracts for further investigation. Tissues 
were fixed in 4% paraformaldehyde before dehydration 
in ethanol and xylene prior to paraffin embedding. 
Immunohistochemistry was performed as previously 
described [33]. Briefly, tissues were sectioned and 
rehydrated in a gradient of ethanol prior to antigen 
retrieval and peroxidase block. Sections were incubated 
in primary antibody overnight at 4° C (Suppl. Table 2) 
before detection via biotinylated secondary antibody 
(1:200, Vector Laboratories (Burlingame, CA) and ABC 
peroxidase (Vector Laboratories). Targets were visualized 
via 3,3’-diaminobenzidine (DAB, Vector Laboratories) 
and counterstained with hematoxylin.
Statistics
All data are displayed as mean ± standard error. 
Significance for in vitro proliferation and anchorage 
independent growth assays was determined via paired 
t-test utilizing Prism software (GraphPad, La Jolla, CA). 
All data sets were analyzed for significant outliers by 
Grubbs’ test of deviation.
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